Comparable Company Analysis for Hong Kong IPOs: Avoiding Benchmarking Errors

The selection of comparable companies for a Hong Kong IPO valuation is not a theoretical exercise — it is the single most contested input in the price discovery process between sponsors and cornerstone investors, and the margin for error has narrowed sharply. In the 2025-2026 listing cycle, HKEX has intensified its scrutiny of valuation methodologies under Listing Decision LD143-2024, which explicitly requires sponsors to justify the selection criteria for each comparable company in the valuation section of the prospectus. This follows a broader trend: between 2022 and 2024, the SFC issued at least seven deficiency letters to sponsors specifically citing inadequate or inconsistent comparable company analysis (CCA), leading to delayed listing timelines and, in two cases, withdrawn applications. The issue is not merely regulatory. Market conditions have shifted. As of Q1 2026, the Hang Seng Index trades at a trailing P/E of 9.8x, while the Hang Seng Tech Index sits at 18.2x — a dispersion that masks extreme intra-sector valuation gaps. For a biotech issuer on the Main Board under Chapter 18C, a mis-specified peer set can swing the implied valuation by 40% to 60%, directly affecting the placement price and post-listing liquidity. This article dissects the mechanics of CCA for Hong Kong IPOs, identifies the most common benchmarking errors, and provides a framework grounded in HKEX Listing Rules and market practice.

The Structural Logic of Comparable Company Analysis in Hong Kong IPOs

Comparable company analysis serves as the primary valuation anchor for the majority of Hong Kong Main Board listings, particularly for issuers without a direct public market precedent. The HKEX Listing Rules, specifically Chapter 9 (Equity Securities Listing), do not prescribe a mandatory valuation methodology, but Practice Note 21 (PN21) on profit forecasts and valuations requires that any valuation included in a prospectus must be “fair, reasonable, and supported by adequate data.” In practice, this means the sponsor must demonstrate that the peer group is homogeneous in business model, revenue profile, growth trajectory, and risk exposure.

Why CCA Dominates Over DCF in Hong Kong Prospectuses

Discounted cash flow (DCF) analysis is rarely the sole methodology in a Hong Kong IPO prospectus for two structural reasons. First, the majority of Hong Kong-listed issuers are from the PRC, and many operate under VIE structures or through Cayman-incorporated holding companies with PRC operating entities. Cash flow repatriation restrictions under PRC State Administration of Foreign Exchange (SAFE) Circular 37 and the 2015 Foreign Investment Law create uncertainty in terminal value assumptions that sponsors cannot easily model with defensible inputs. Second, the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (Chapter 571, subsidiary legislation) imposes a duty on sponsors to ensure that all information in a prospectus is not misleading. A DCF model with subjective terminal growth rates and WACC assumptions — often varying by 200-300 bps between analysts — is harder to defend in a deficiency letter than a CCA anchored to observable market multiples.

According to a 2025 review by the Hong Kong Institute of Certified Public Accountants (HKICPA), 83% of prospectuses filed for Main Board listings between January 2023 and June 2025 included a CCA as the primary valuation methodology, with DCF used only as a supporting cross-check. This is a notable increase from 67% in the 2018-2020 period, reflecting sponsors’ preference for methodologies that can be benchmarked against actual traded securities.

The Regulatory Requirement for Homogeneity

The SFC’s December 2024 thematic review of IPO valuation practices identified “inconsistent peer selection” as the second most common deficiency, cited in 31% of reviewed prospectuses. The review specifically flagged cases where sponsors included companies with fundamentally different revenue drivers — for example, placing a SaaS platform with 80% recurring revenue alongside a hardware-dependent IT services firm trading at 12x EBITDA. The HKEX’s Listing Committee has since issued guidance through LD143-2024 stating that the sponsor must provide a “clear rationale for inclusion and exclusion of each comparable company,” including a tabular comparison of revenue composition, gross margin, operating leverage, and geographic exposure.

Common Benchmarking Errors in Hong Kong IPO CCA

Error 1: Geographic Mismatch in the Peer Set

The most frequent error in CCA for Hong Kong IPOs is the inclusion of comparables from developed markets — particularly the US and EU — without adjusting for the structural risk premium embedded in PRC-based issuers. A sponsor proposing a PRC consumer-tech issuer may include US-listed peers such as PDD Holdings (NASDAQ: PDD) or Meituan (HKEX: 3690) without accounting for the regulatory risk differential. PRC-based issuers face a regulatory overlay that includes the Cyberspace Administration of China (CAC) data security reviews, the Anti-Monopoly Law amendments of 2022, and the 2023 revision of the PRC Securities Law, which imposes extraterritorial data disclosure restrictions. These factors compress valuation multiples by an estimated 15-25% relative to US peers, according to a 2025 study by the University of Hong Kong’s Faculty of Law.

The correct approach is to construct a peer set that is either entirely PRC-based (A-share, H-share, or US-listed PRC ADRs) or to apply a documented country risk discount. The HKEX’s Listing Division has accepted the use of a sovereign CDS spread adjustment in at least three Chapter 18C filings in 2025, where the sponsor applied a discount equal to the 5-year PRC sovereign CDS spread (approximately 35 bps as of March 2026) to the median EV/Revenue multiple of the US peer group.

Error 2: Ignoring the VIE Structure Premium or Discount

For issuers operating through a VIE structure — which remains common for PRC companies in sectors such as education, internet, and media where foreign ownership is restricted — the comparable set must account for the structural risk embedded in the VIE contractual arrangements. The SFC’s 2023 guidance on VIE disclosures (circular dated 15 June 2023) requires sponsors to explicitly state in the prospectus that VIE shareholders do not hold direct equity ownership in the PRC operating entities. This legal risk translates into a valuation discount.

A 2025 empirical analysis by Deloitte China found that VIE-structured companies listing on HKEX trade at a median 18% discount to their non-VIE peers with comparable revenue and EBITDA profiles. Sponsors who fail to apply this discount in their CCA — or who include non-VIE comparables without adjustment — invite deficiency letters. In the 2024 filing of a PRC education technology issuer, the sponsor initially proposed a peer set that included both VIE and non-VIE companies without adjustment. The SFC required a revised valuation section that separated the two groups and applied a 20% discount to the non-VIE comparables.

Error 3: Using Trailing Multiples Without Forward-Looking Adjustments

Hong Kong IPO prospectuses are typically filed with financial data covering the most recent three completed fiscal years. However, the valuation section must also incorporate forward-looking information, as required by Listing Rule 11.06, which mandates that the prospectus contain “all information necessary to enable an investor to make an informed assessment of the issuer’s financial condition and prospects.” A CCA that relies solely on trailing P/E or EV/EBITDA multiples — without adjusting for expected growth differentials — produces a misleading comparison.

Consider a biotech issuer under Chapter 18C with no approved product revenue but a late-stage pipeline. Using trailing EV/Sales is meaningless because sales are zero. The correct approach is to use forward EV/EBITDA or EV/Revenue based on consensus estimates for the next 12-24 months, sourced from a recognized data provider such as Bloomberg or FactSet. The SFC’s 2024 thematic review noted that 12% of reviewed prospectuses used trailing multiples exclusively, and in each case the sponsor was required to supplement the analysis with forward multiples and a PEG ratio comparison.

Constructing a Defensible CCA Framework for Hong Kong Listings

Step 1: Define the Peer Universe with Explicit Filters

The first step is to define the universe of potential comparables using objective, auditable filters. The sponsor should document the following criteria in the valuation section of the prospectus:

• Listing venue: Include only companies listed on HKEX Main Board, GEM, or recognized international exchanges (NYSE, NASDAQ, LSE, SSE, SZSE). Exclude OTC or unlisted entities.
• Business model: Require that at least 70% of revenue is derived from the same business segment as the issuer.
• Revenue size: Exclude companies with revenue less than 20% or more than 500% of the issuer’s revenue, to avoid size-based valuation distortions.
• Growth profile: Exclude companies with a 3-year revenue CAGR below 50% or above 200% of the issuer’s CAGR, unless a documented adjustment is applied.

These filters should be presented in a table within the prospectus, showing the number of companies excluded at each filter stage and the rationale. This approach was accepted by the HKEX in the 2025 listing of a PRC SaaS company (HKEX: 25XX), where the sponsor started with 47 potential comparables and narrowed to 8 after applying the filters.

Step 2: Select the Appropriate Multiple

The choice of valuation multiple depends on the issuer’s profitability stage and industry. For profitable issuers, EV/EBITDA is the standard primary multiple because it neutralizes differences in capital structure and depreciation policies. For loss-making issuers — common in Chapter 18C biotech and Chapter 18A pre-revenue companies — the appropriate multiple is EV/Revenue, with a secondary analysis using EV/Sales-to-Growth (PEG) ratio.

The HKEX has accepted the use of EV/EBITDAR (earnings before interest, taxes, depreciation, amortization, and rental expenses) for asset-heavy issuers such as logistics companies, where rental costs are a significant operating expense. This was applied in the 2025 filing of a PRC logistics firm, where the sponsor used EV/EBITDAR to compare the issuer against listed logistics peers with varying lease structures.

Step 3: Apply Statistical Measures and Sensitivity Analysis

A single median multiple is insufficient. The prospectus should present the mean, median, 25th and 75th percentiles of the peer group multiples, along with the interquartile range. This provides the investor with a range rather than a false point estimate. The sponsor should also conduct a sensitivity analysis showing how the implied valuation changes if the peer group is expanded or contracted by one standard deviation.

In the 2025 filing of a PRC electric vehicle (EV) manufacturer, the sponsor presented a CCA using 12 global EV peers. The median EV/Revenue multiple was 1.8x, but the 25th percentile was 1.2x and the 75th percentile was 2.5x. The sponsor then applied a 10% discount for the issuer’s smaller production scale and a 5% discount for its reliance on a single battery supplier, resulting in an implied valuation of 1.4x EV/Revenue. The HKEX accepted this approach without further deficiency letters.

The Role of Cornerstone Investors in Validating the CCA

Cornerstone investors — institutional investors who commit to subscribing to a fixed number of shares before the IPO — effectively serve as a market test of the CCA. Under HKEX Listing Rule 9.11(4), the cornerstone investment agreement must be disclosed in the prospectus, including the pricing mechanism. If the cornerstone price is set at a discount to the implied CCA valuation, the sponsor must explain the rationale.

In the 2025 listing of a PRC healthcare services company, the cornerstone investors subscribed at a 12% discount to the midpoint of the CCA-derived valuation range. The sponsor justified this discount by noting that the issuer’s revenue growth was projected to decelerate from 35% to 22% in the next fiscal year, which was not fully captured by the trailing multiples of the peer group. The HKEX accepted this explanation, but required the prospectus to include a sensitivity table showing the implied valuation under different growth scenarios.

Actionable Takeaways

1. Construct the comparable company peer set using objective, auditable filters — listing venue, business model, revenue size, and growth profile — and present the exclusion rationale in a tabular format to preempt SFC deficiency letters.
2. Apply a documented country risk discount when including non-PRC comparables, using the 5-year PRC sovereign CDS spread or an equivalent market-based adjustment.
3. For VIE-structured issuers, separate the peer set into VIE and non-VIE groups and apply a minimum 18% discount to the non-VIE comparables, supported by empirical data from recognized sources.
4. Use forward multiples — EV/EBITDA or EV/Revenue based on consensus estimates for the next 12-24 months — as the primary metric, not trailing multiples, and include a PEG ratio comparison for growth-stage issuers.
5. Present the peer group’s mean, median, 25th and 75th percentiles, and interquartile range, along with a sensitivity analysis showing the impact of expanding or contracting the peer set by one standard deviation.